Anticholinergic Medication Burden and Cognitive Subtypes in Parkinson's Disease Without Dementia

Overview

Journal Arch Clin Neuropsychol

Publisher Oxford University Press

Specialties Neurology
Psychology

Date 2024 May 27

PMID 38797973

Authors

Lauren G Santos

Lauren E Kenney

Alyssa Ray

Alfredo Paredes

Adrianna M Ratajska

Kara Eversole

Bhavana Patel

Ashley E Rawls

Michael S Okun

Dawn Bowers

Affiliations

Soon will be listed here.

Abstract

Objective: Cognitive changes are heterogeneous in Parkinson's disease (PD). This study compared whether anticholinergic burden drives differences in cognitive domain performance and empirically-derived PD-cognitive phenotypes.

Method: A retrospective chart review contained participants (n = 493) who had idiopathic PD without dementia. Participants' medications were scored (0-3) and summed based on the anticholinergic cognitive burden scale (ACBS). We examined the ACBS' relationship to five cognitive domain composites (normative z-scores) and three (K-means clustering based) cognitive phenotypes: cognitively intact, low executive function (EF), and predominately impaired EF/memory. Analyses included Spearman correlations, analysis of covariance, and Pearson chi-squared test.

Results: Overall, phenotypes did not differ in anticholinergic burden, and (after false-discovery-rate corrections) no cognitive domains related. When comparing those above and below the clinically relevant ACBS cutoff (i.e., score ≥3), no significant phenotype or domain differences were found.

Conclusions: Anticholinergic medication usage did not drive cognitive performance in a large clinical sample of idiopathic PD without dementia.

References

Svenningsson P, Westman E, Ballard C, Aarsland D . Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012; 11(8):697-707. DOI: 10.1016/S1474-4422(12)70152-7. View

Sheu J, Tsai M, Erickson S, Wu C . Association between Anticholinergic Medication Use and Risk of Dementia among Patients with Parkinson's Disease. Pharmacotherapy. 2019; 39(8):798-808. DOI: 10.1002/phar.2305. View

Shah R, Janos A, Kline J, Yu L, Leurgans S, Wilson R . Cognitive decline in older persons initiating anticholinergic medications. PLoS One. 2013; 8(5):e64111. PMC: 3669362. DOI: 10.1371/journal.pone.0064111. View

van der Zee S, Kanel P, Gerritsen M, Boertien J, Slomp A, Muller M . Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment. Mov Disord. 2022; 37(4):713-723. PMC: 9306739. DOI: 10.1002/mds.28913. View

Petrou M, Bohnen N, Muller M, Koeppe R, Albin R, Frey K . Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology. 2012; 79(11):1161-7. PMC: 3525303. DOI: 10.1212/WNL.0b013e3182698d4a. View

Goldman J, Vernaleo B, Camicioli R, Dahodwala N, Dobkin R, Ellis T . Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. NPJ Parkinsons Dis. 2018; 4:19. PMC: 6018742. DOI: 10.1038/s41531-018-0055-3. View

Norling A, Bennett A, Crowe M, Long D, Nolin S, Myers T . Longitudinal associations of anticholinergic medications on cognition and possible mitigating role of physical activity. J Am Geriatr Soc. 2023; 71(6):1937-1943. PMC: 10258136. DOI: 10.1111/jgs.18279. View

Pourzinal D, Yang J, Byrne G, OSullivan J, Mitchell L, McMahon K . Identifying subtypes of mild cognitive impairment in Parkinson's disease using cluster analysis. J Neurol. 2020; 267(11):3213-3222. DOI: 10.1007/s00415-020-09977-z. View

Muller M, Bohnen N . Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep. 2013; 13(9):377. PMC: 3991467. DOI: 10.1007/s11910-013-0377-9. View

10.

van der Zee S, Muller M, Kanel P, van Laar T, Bohnen N . Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease. Mov Disord. 2020; 36(3):642-650. PMC: 7988481. DOI: 10.1002/mds.28360. View

11.

Broder J, Ryan J, Shah R, Lockery J, Orchard S, Gilmartin-Thomas J . Anticholinergic medication burden and cognitive function in participants of the ASPREE study. Pharmacotherapy. 2021; 42(2):134-144. PMC: 8863638. DOI: 10.1002/phar.2652. View

12.

Okkels N, Grothe M, Taylor J, Hasselbalch S, Fedorova T, Knudsen K . Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes. Brain. 2024; 147(7):2308-2324. DOI: 10.1093/brain/awae069. View

13.

Legault-Denis C, Aghourian M, Soucy J, Rosa-Neto P, Dagher A, Aumont E . Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [F]-FEOBV. Parkinsonism Relat Disord. 2021; 91:162-166. DOI: 10.1016/j.parkreldis.2021.09.018. View

14.

Jones J, Tanner J, Okun M, Price C, Bowers D . Are Parkinson's Patients More Vulnerable to the Effects of Cardiovascular Risk: A Neuroimaging and Neuropsychological Study. J Int Neuropsychol Soc. 2017; 23(4):322-331. PMC: 5729910. DOI: 10.1017/S1355617717000017. View

15.

Dubois B, PILON B, LHERMITTE F, Agid Y . Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol. 1990; 28(2):117-21. DOI: 10.1002/ana.410280202. View

16.

de Germay S, Montastruc J, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F . Atropinic (Anticholinergic) Burden in Parkinson's Disease. Mov Disord. 2016; 31(5):632-6. DOI: 10.1002/mds.26595. View

17.

Halliday G, Leverenz J, Schneider J, Adler C . The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014; 29(5):634-50. PMC: 4049032. DOI: 10.1002/mds.25857. View

18.

Pasquini J, Brooks D, Pavese N . The Cholinergic Brain in Parkinson's Disease. Mov Disord Clin Pract. 2021; 8(7):1012-1026. PMC: 8485627. DOI: 10.1002/mdc3.13319. View

19.

Moriarty F, Savva G, Grossi C, Bennett K, Fox C, Maidment I . Cognitive decline associated with anticholinergics, benzodiazepines and Z-drugs: Findings from The Irish Longitudinal Study on Ageing (TILDA). Br J Clin Pharmacol. 2020; 87(7):2818-2829. DOI: 10.1111/bcp.14687. View

20.

Pondal M, del Ser T, Bermejo F . Anticholinergic therapy and dementia in patients with Parkinson's disease. J Neurol. 1996; 243(7):543-6. DOI: 10.1007/BF00886877. View